Javascript must be enabled to continue!
Blueberry Attenuates Liver Fibrosis, Protects Intestinal Epithelial Barrier, and Maintains Gut Microbiota Homeostasis
View through CrossRef
Objective. Recently, blueberry has been identified as a candidate for the treatment of liver fibrosis. Given the role of gut-liver axis in liver fibrosis and the importance of the gut microbiota homeostasis to the maintenance of the intestinal epithelial barrier, this study aimed to investigate whether blueberry could attenuate liver fibrosis and protect the intestinal epithelial barrier by maintaining the homeostasis of the gut microbiota.Method. A CCl4-induced rat liver fibrosis model was used to detect the roles of blueberry in liver fibrosis and intestinal epithelial barrier. The liver weight and body weight were measured, the liver function was monitored by ALT and AST activity, protein and mRNA were determined by western blot and RT-qPCR, and the gut microbiome was detected by Miseq.Results. The results showed that blueberry could reduce the rate of liver weight/body weight gain (p<0.05), ALT (p<0.01) and AST (p<0.05) activity, and the expression of collagen I (p<0.01), collagen IV (p<0.01), andα-SMA (p<0.01) expression in CCl4-induced rat liver. CCl4impaired the intestinal epithelial barrier and decreased the expression of the tight junction protein. Blueberry restored the intestinal epithelial barrier and increased the expression of the tight junction protein. The gut microbiota homeostasis was impaired by CCl4, but after treatment with blueberry, the intestinal flora returned to normal.Conclusion. Blueberry attenuated liver fibrosis, protected intestinal epithelial barrier, and maintained the homeostasis of the gut microbiota in a CCl4-induced injury rat model.
Title: Blueberry Attenuates Liver Fibrosis, Protects Intestinal Epithelial Barrier, and Maintains Gut Microbiota Homeostasis
Description:
Objective.
Recently, blueberry has been identified as a candidate for the treatment of liver fibrosis.
Given the role of gut-liver axis in liver fibrosis and the importance of the gut microbiota homeostasis to the maintenance of the intestinal epithelial barrier, this study aimed to investigate whether blueberry could attenuate liver fibrosis and protect the intestinal epithelial barrier by maintaining the homeostasis of the gut microbiota.
Method.
A CCl4-induced rat liver fibrosis model was used to detect the roles of blueberry in liver fibrosis and intestinal epithelial barrier.
The liver weight and body weight were measured, the liver function was monitored by ALT and AST activity, protein and mRNA were determined by western blot and RT-qPCR, and the gut microbiome was detected by Miseq.
Results.
The results showed that blueberry could reduce the rate of liver weight/body weight gain (p<0.
05), ALT (p<0.
01) and AST (p<0.
05) activity, and the expression of collagen I (p<0.
01), collagen IV (p<0.
01), andα-SMA (p<0.
01) expression in CCl4-induced rat liver.
CCl4impaired the intestinal epithelial barrier and decreased the expression of the tight junction protein.
Blueberry restored the intestinal epithelial barrier and increased the expression of the tight junction protein.
The gut microbiota homeostasis was impaired by CCl4, but after treatment with blueberry, the intestinal flora returned to normal.
Conclusion.
Blueberry attenuated liver fibrosis, protected intestinal epithelial barrier, and maintained the homeostasis of the gut microbiota in a CCl4-induced injury rat model.
Related Results
Modern Principles of Liver Fibrosis Diagnosis in Patients With Chronic Diffuse Liver Lesions: Literature Review and Clinical Case Description
Modern Principles of Liver Fibrosis Diagnosis in Patients With Chronic Diffuse Liver Lesions: Literature Review and Clinical Case Description
Introduction. Chronic diffuse liver lesions, which is at a certain stage and phase of the disease characterized by excessive accumulation of components of the extracellular matrix,...
Causal relationship between gut microbiota and malignant lymphoma:a two-way two-sample Mendelian randomization study
Causal relationship between gut microbiota and malignant lymphoma:a two-way two-sample Mendelian randomization study
Abstract
Background
The significance of gut microbiota in human health is gaining attention, leading to a rise in observational and clinical studies focused on understandi...
The Microbiota and Microbiome in COVID-19 in Adults and Children and Potential Therapeutic Interventions: A Review
The Microbiota and Microbiome in COVID-19 in Adults and Children and Potential Therapeutic Interventions: A Review
The work presented is a comprehensive review of the role of the human microbiota in the context of the COVID-19 pandemic. A diverse microbial community heavily colonizes the human ...
(051) Gut Microbiota and Sexual Desire Disorder in Women
(051) Gut Microbiota and Sexual Desire Disorder in Women
Abstract
Introduction
Hyposexual desire disorder (HSDD) is a common female sexual health problem. HSDD mainly refers to women's ...
Characterization of the intestinal microbiota in MSM with HIV infection
Characterization of the intestinal microbiota in MSM with HIV infection
Abstract
Background
HIV-infected persons demonstrate notable disturbances in their intestinal microbiota; however, the impact of intestinal microbio...
Initial study of biexponential model of intravoxel incoherent motion magnetic resonance imaging in evaluation of the liver fibrosis
Initial study of biexponential model of intravoxel incoherent motion magnetic resonance imaging in evaluation of the liver fibrosis
Background
The diagnosis of liver fibrosis is a difficult task at any time using conventional clinical imaging. Intravoxel incoherent motion (IVIM) can be used to inves...
Effect of Qizhu Granule on Liver Sinusoidal Endothelial Cells Capillarization in Carbon Tetrachloride-Induced Rats Fibrosis.
Effect of Qizhu Granule on Liver Sinusoidal Endothelial Cells Capillarization in Carbon Tetrachloride-Induced Rats Fibrosis.
Abstract
Background: Qizhu granule, a traditional Chinese medicine, has been widely used in clinic as a complementary and alternative medicine to treat liver fibrosis.Howev...
A bioactive product lipoxin A4 attenuates liver fibrosis in an experimental model by regulating immune response and modulating the expression of regeneration genes
A bioactive product lipoxin A4 attenuates liver fibrosis in an experimental model by regulating immune response and modulating the expression of regeneration genes
Background/Aims: Lipoxin A4 (LXA4), an anti-inflammatory lipid mediator, regulates leukocyte cellular activity and activates gene transcription. The therapeutic effect of LXA4 on l...

